Revvity Inc. (NYSE: RVTY) shares fell more than 2% in intra-day trading on Monday, even after the company posted third-quarter adjusted earnings that topped expectations and raised its full-year profit outlook.

The health science solutions provider reported adjusted earnings of $1.18 per share, surpassing the analyst consensus of $1.14. Revenue came in at $699 million, roughly in line with expectations of $699.39 million and up 2% from the prior-year quarter. Organic revenue growth increased 1% year-over-year.

The Diagnostics division led performance with a 3% rise in revenue to $356 million, while the Life Sciences segment posted a 1% increase to $343 million. Both segments, however, saw year-over-year declines in adjusted operating margins.

Revvity updated its 2025 revenue forecast to a range of $2.83 billion to $2.88 billion, reflecting foreign exchange adjustments, while maintaining its organic growth outlook of 2-4%. The company raised its adjusted earnings guidance to $4.90-$5.00 per share, above the consensus estimate of $4.87.